ISCBH HOME
Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France, the venue for ICCBH Bone School 2023 on 29-31 May 2023

Programme

Due to the 2023 Bone School being over subscribed, for next year’s School there will be a process of application for delegates.  If you are interested in attending please complete the application form and return it by 31 October 2024.  Successful applicants will be notified by 30 November 2024 that they have been accepted to join the 2025 ISCBH Bone School.

The Bone School faculty comprises a group of internationally renowned paediatricians, endocrinologists and biochemists, who between them will discuss the full range of paediatric bone disorders. The programme includes lectures, discussions and case presentations. The number of places will be limited to encourage opportunities for interaction. Attendees are encouraged to submit cases for discussion. Frequent breaks and evening events will give you plenty of opportunity to network.

The 2025 Bone School will commence on Wednesday 28 May in the morning at 08:30 and will end on Friday 30 May at 12:45.

We encourage our delegates to arrive on the Tuesday afternoon or evening so that all attendees are ready to start promptly at 08:30 on Wednesday morning.  We will have an informal Welcome and Buffet dinner on Tuesday evening from 18:00 to give all an early opportunity to get together and meet!

We will serve an informal sandwich buffet lunch on the final day for those who wish to have some refreshments prior to departing. Lunch service on the last day will end at 14:00.

The Programme Overview from our last school can be found below – the final 2025 programme is to be confirmed but will follow a similar format.  

PROGRAMME OVERVIEW
MEET THE FACULTY

Additional resources for registered delegates

Click on the button below to access the directory of additional resources. This directory is password protected and is only available to registered delegates of the 2025 ISCBH Bone School.

ADDITIONAL RESOURCES

Case presentations

There will be opportunities for participants to present their own cases.  

Clinical case discussions are an important learning tool and all participants are encouraged to submit a clinical case for presentation and discussion.

These presentations will be based on the following categories:

  • Primary osteoporosis
  • Secondary osteoporosis
  • Rickets
  • Calcium disorders
  • Phosphate disorders
  • Disorders of bone mass
  • Growth plate disorders (primary)
  • Calcification or ossification disorders

Candidates should list an interesting case topic from at least three of the categories and we will contact participants on the final chosen topic. Detailed guidelines will be given at the same time and the candidate will then be asked to provide a detailed submission summarizing the chosen case and relevant learning points. Cases adjudged to be relevant to the course and of high quality by the ISCBH steering group will be invited for presentation during the course. A prize will be offered for the best presentation.

Please do not hesitate to contact us in case of any queries.

Case Manager: Ciara McDonnell (Dublin, Ireland)

APPLICATION FORM

Who should attend?

Clinical paediatric adult and endocrine trainees and fellows with an interest in bone disease

Clinical and translational researchers

The Bone school aims to supplement a working knowledge of bone metabolism and skeletal disorders. Therefore the course is best suited to the following groups:

  • Senior (Year3+) Trainees in paediatric or adult endocrinology or relative specialities (genetics/ metabolic/orthopaedics)
  • Clinical fellows with an interest in bone disease
  • Postdoctoral clinical and translational researchers in fields related to bone metabolism or skeletal disorders

Numbers will be limited to 48 delegates in order to promote interaction and discussion both within and outside the lecture theatre. Participants will have the opportunity to learn from and interact with some of leading experts in the field.

ISCBH HOME

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

© 2023 International Society for Children’s Bone Health

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE